Time to Next Treatment

Uses

How it works

Benefits

Evidence quality

Other

Highlighted claims

• Time to next treatment is defined as time from enrolment to the next treatment or death from any cause. — Blood Cancer Clinical Trials Long-term Follow-up Using Integrated Healthcare Systems Data (BLISS): protocol for a data-linkage study integrating randomised clinical trials with national healthcare systems data
• Time to next treatment will be derived from systemic anticancer therapy data and evaluated as a surrogate endpoint for progression-free survival. — Blood Cancer Clinical Trials Long-term Follow-up Using Integrated Healthcare Systems Data (BLISS): protocol for a data-linkage study integrating randomised clinical trials with national healthcare systems data
• Line of treatment will be identified from systemic anticancer therapy records using rules based on intervals between regimen changes and line-of-treatment index agents. — Blood Cancer Clinical Trials Long-term Follow-up Using Integrated Healthcare Systems Data (BLISS): protocol for a data-linkage study integrating randomised clinical trials with national healthcare systems data
• Surrogacy assessment requires evidence that treatment effects and individual prognosis align between time to next treatment and progression-free survival. — Blood Cancer Clinical Trials Long-term Follow-up Using Integrated Healthcare Systems Data (BLISS): protocol for a data-linkage study integrating randomised clinical trials with national healthcare systems data
• Time to next treatment may be useful because it is easier and cheaper to measure routinely than progression-free survival. — Blood Cancer Clinical Trials Long-term Follow-up Using Integrated Healthcare Systems Data (BLISS): protocol for a data-linkage study integrating randomised clinical trials with national healthcare systems data